Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma

To overcome radioresistance in the treatment of osteosarcoma, a primary malignant tumor of the bone, radiotherapy is generally combined with radiosensitizers. The purpose of this study was to investigate a third-generation bisphosphonate, zoledronic acid (ZOL), as a radiosensitizer for osteosarcoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Ho, Kim, Mi-Sook, Lee, Kyung-Hee, Koh, Jae-Soo, Jung, Won-Gyun, Kong, Chang-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342595/
https://www.ncbi.nlm.nih.gov/pubmed/27765919
http://dx.doi.org/10.18632/oncotarget.12281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342595/
https://www.ncbi.nlm.nih.gov/pubmed/27765919
http://dx.doi.org/10.18632/oncotarget.12281

Ejemplares similares